Related Experiment Video

Updated: Nov 25, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes

Ferdinandos Skoulidis¹

¹The University of Texas MD Anderson Cancer Center, Houston, Texas. fskoulidis@mdanderson.org.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|December 17, 2020

Abstract:

Using transcriptional profiling, three robust subtypes of nonsquamous non-small cell lung cancer were defined, independently of initiating oncogenic driver events. Subtype-specific differential sensitivity to MEK1/2 inhibitors was reported and an interaction between the mucinous subtype, STK11/LKB1 genomic alterations, and inferior clinical outcomes with atezolizumab in the OAK clinical trial was identified.See related article by Daemen et al., p. 1162.

More Related Videos

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Articles linked to this work by shared authors, journal, and citation graph.

Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT).

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Cancer Chemoimmunotherapy: Time Will Tell.

Cancer immunology research·2026

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need.

Lung cancer (Amsterdam, Netherlands)·2026

Comprehensive profiling of AML and T-cell states across disease stages in acute myeloid leukemia using spectral flow cytometry.

Blood immunology & cellular therapy·2026

RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma.

Cancer cell·2026

Real-World Experience of Tarlatamab in Extensive-Stage Small Cell Lung Carcinoma Showed Promising Systemic and Intracranial Efficacy With Higher Neurologic Toxicity.

JCO precision oncology·2026

See all related articles